Germany: Dearer Drug Prescribing?

25 September 1994

The pressure on German doctors from the Health Structure Law to be economic in prescribing is easing as they prescribe more and more costly drugs, says Heidelberg pharmacologist Ulrich Schwabe, in his 1994 report on prescribing. In addition to the prescribing of more expensive drugs, the evidence shows that generics are in retreat and are losing market share, he says. In first-half 1994, western German drug sales rose 7.3% or 800 million Deutschemarks ($518.3 million) over first-half 1993.

Dr Schwabe's claim is rejected by the association of research-based drugmakers for failing to discriminate among products. it says doctors are using modern drugs for which there are no generic copies.

Meantime, a report by the local health funds' scientific institute says patients will contribute about 3 billion marks ($1.9 billion) to their total drug costs in 1994, an increase of around 800 million marks over last year and a tripling of the 1992 contribution. On average, people are paying a tenth of the cost of their drugs in western Germany, and 8.7% in the eastern states.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight